You are viewing the site in preview mode

Skip to main content


We're creating a new version of this page. See preview

  • Poster presentation
  • Open Access

Efavirenz’ adverse reactions: a possible link between depression and gynecomastia

  • 1Email author,
  • 2,
  • 1, 2,
  • 1, 2 and
  • 1, 2
BMC Infectious Diseases201414 (Suppl 7) :P27

  • Published:


  • Dopamine
  • Testosterone
  • Adverse Reaction
  • Prolactin
  • Efavirenz


Reports show that 1.8–8.4% of male patients receiving efavirenz (EFV) develop gynecomastia by unclear multiple mechanisms, one of them being a direct binding to estrogen receptors. However, EFV can independently cause gynecomastia by increasing prolactin levels and we postulate that this mechanism is a dopamine-mediated one. Dopamine is a strong prolactin inhibitor. Conversely, a lack of dopamine can cause hyperprolactinemia. On the other hand, dopamine is an antidepressant neurotransmitter and depression is one of the very frequent adverse reactions to EFV. We present the case of an HIV-positive newly diagnosed male patient who developed mild depression and amplified a preexistent gynecomastia after the introduction of an EFV-containing antiretroviral regimen.

Case report

A 41-year-old male patient, diagnosed with CDC-A2 HIV infection, had been receiving antiretroviral treatment (ART) for 14 months with ABC+3TC+EFV and had been favorably evaluated regarding the immuno-virological course. Nevertheless, after 6 months of ART he developed bilateral gynecomastia with mastodynia and he reported also mild depression. A careful anamnesis discovered a previous mild gynecomastia with also mild rising in prolactin level. Current clinical examination showed moderate bilateral concentric gynecomastia. The breast echography was normal. Brain MRI was performed and can’t exclude microprolactinoma. Lab findings showed normal levels of estrogen and testosterone and high levels of prolactin. We considered dropping EVF and replacing it with raltegravir. After switching (raltegravir doesn’t affect the endocrine ax) mastodynia ceased in one month, the breast volume regressed in 2-3 months and the prolactin level decreased. Besides, the depression’s symptoms diminished.


In the presented case, gynecomastia was related to hyperprolactinemia and the last was related to EFV use. Moreover, the patient presented also an EFV related depression. It makes sense to consider a unique mechanism for both EFV’s adverse reactions: a drop in dopamine-level caused by EFV, which produce depression and also a hyperprolactinemia with gynecomastia.



This paper is realized as a part of doctoral projects - POSDRU/159/1.5/S/137390.

Authors’ Affiliations

National Institute for Infectious Diseases "Prof. Dr. Matei Balş", Bucharest, Romania
Carol Davila University of Medicine and Pharmacy, Bucharest, Romania


© Diaconu et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.